Paradoxical effects of constitutive human IL-32γ in transgenic mice during experimental colitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 49, 2010, Pages 21082-21086

  Choi, Jida ^a   Bae, Suyoung ^a   Hong, Jaewoo ^a   Ryoo, Soyoon ^a   Jhun, Hyunjhung ^a   Hong, Kwangwon ^a   Yoon, Doyoung ^a   Lee, Siyoung ^b   Her, Erk ^b   Choi, Wonhyuk ^c   Kim, Jeonghwan ^c   Azam, Tania ^d   Dinarello, Charles A ^a,d   Kim, Soohyun ^a  

^a Konkuk University   (South Korea)

^b Department of Immunology ^*  (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Innate immunity; Intestinal barrier

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 32; INTERLEUKIN 32GAMMA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TRANSGENIC MOUSE;

ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; HUMANS; INFLAMMATION; INTERLEUKINS; MICE; MICE, TRANSGENIC; SURVIVAL RATE; TIME FACTORS;

MUS; MUS MUSCULUS;

EID: 78650425216     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1015418107     Document Type: Article

References (33)

1. Pizarro TT, Cominelli F (2007) Cytokine therapy for Crohn's disease: Advances in translational research. Annu Rev Med 58:433-444.
2. Hibi T, Ogata H (2006) Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41:10-16.
3. Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-521.
4. Derkx B, et al. (1993) Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342:173-174.
5. Pastorelli L, Pizarro TT, Cominelli F, Vecchi M (2009) Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 14:505-521.
6. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA (2005) Interleukin-32: A cytokine and inducer of TNFalpha. Immunity 22:131-142.
7. Choi JD, et al. (2009) Identification of the most active interleukin-32 isoform. Immunology 126:535-542.
8. Bai X, et al. (2010) IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol 184:3830-3840.
9. Joosten LA, et al. (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298-3303.
10. Kim S, et al. (2008) Proteinase 3-processed form of the recombinant IL-32 separate domain. BMB Rep 41:814-819.
11. Netea MG, et al. (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1- dependent mechanism. Proc Natl Acad Sci USA 102:16309-16314.
12. Nold MF, et al. (2008) Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 181:557-565.
13. Heinhuis B, et al. (2010) IL-32gamma and Streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2. Ann Rheum Dis 69:1866-1872.
14. Shoda H, et al. (2006) Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 8:R166.
15. Hong J, et al. (2009) Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFa and IL-1β. Cytokine 49:171-176.
16. Nold-Petry CA, et al. (2009) IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci USA 106:3883-3888.
17. Shioya M, et al. (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480-486.
18. Kang JW, et al. (2009) A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 128(1, Suppl)e532-e540.
19. Kobayashi H, et al. (2010) Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS ONE 5:e9458.
20. Cagnard N, et al. (2005) Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/ chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 16:289-292.
21. Mun SH, et al. (2009) Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 60:678-685.
22. Kundu M, Basu J (2006) IL-32: An emerging player in the immune response network against tuberculosis? PLoS Med 3:e274.
23. Netea MG, et al. (2006) Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 3:e277.
24. Calabrese F, et al. (2008) IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:894-901.
25. Netea MG, et al. (2005) NOD2 3020insC mutation and the pathogenesis of Crohn's disease: Impaired IL-1beta production points to a loss-of-function phenotype. Neth J Med 63:305-308.
26. Chae JI, et al. (2010) Downregulation of immune response by the human cytokines Interleukin-32alpha and beta in cell-mediated rejection. Cell Immunol 264:47-53.
27. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765.
28. Naito Y, et al. (2003) Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 18: 560-569.
29. Noti M, Corazza N, Mueller C, Berger B, Brunner T (2010) TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 207: 1057-1066.
30. Mizoguchi E, et al. (2008) TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 134: 470-480.
31. Cho KA, et al. (2010) Orientia tsutsugamushi induced endothelial cell activation via the NOD1-IL-32 pathway. Microb Pathog 49:95-104.
32. Kobayashi KS, et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-734.
33. Munitz A, et al. (2009) Resistin-like molecule alpha decreases glucose tolerance during intestinal inflammation. J Immunol 182:2357-2363.